Product Details
| Product Name:
Bomedemstat |
CAS No.:
1990504-34-1 |
| Supply Ability:
10g |
Release date:
2025/07/22 |
Product Introduction
Bioactivity
| Name | Bomedemstat |
| Description | Bomedemstat (IMG-7289) is an orally active, irreversible inhibitor of lysine-specific demethylase 1 (LSD1) that exhibits antineoplastic activities in mouse models of myeloproliferative neoplasms (MPNs), and can be used for research on acute myelogenous leukemia (AML) and myelofibrosis (MF) [1]. |
| In vitro | Bomedemstat (IMG-7289) selectively inhibits proliferation and induces apoptosis of JAK2 V617F cells by concomitantly increasing expression and methylation of p53, and, independently, the pro-apoptotic factor PUMA and by decreasing the levels of its antiapoptotic antagonist BCL-XL [1]. Bomedemstat (25 nM, 50 nM) and Ruxolitinib (175 nM) synergistically inhibit JAK2 V617F -driven proliferation [1]. Bomedemstat (50 and 100 nM) exerts a pro-apoptotic effect on 3 key regulators of programmed cell death, TP53, BCL-XL, and PUMA [1]. Cell Viability Assay [1] Cell Line: The human cell lines SET-2 (ATCC 608) and HEK293 Concentration: 25 nM, 50 nM Incubation Time: 96 hours Result: 25 nM alone significantly reduced colony formation. Western Blot Analysis [1] Cell Line: SET-2 cells Concentration: 50 and 100 nM Incubation Time: Result: Decreased levels of the antiapoptotic protein BCL-XL and increased levels of the pro-apoptotic protein PUMA. |
| In vivo | Once-daily treatment with IMG-7289 normalized or improved blood cell counts, reduced spleen volumes, restored normal splenic architecture, and reduced bone marrow fibrosis. Most importantly, LSD1 inhibition lowered mutant allele burden and improved survival [1]. Animal Model: Mx1cre-Jak2 V617F mice [1] Dosage: 45 mg/kg Administration: Administered daily by oral gavage for either 14, 42, or 56 consecutive days Result: In this Mx-Jak2V617F model of myeloproliferative neoplasm (MPN), mice developed severe splenomegaly (up to 10-fold increase in spleen weight). Splenic architecture was completely destroyed, eliminating demarcation of the white and red pulp. Treatment significantly reduced splenomegaly with a few treated mice normalizing their spleen weight. Remarkably, the 56-day course led to partial restoration of lymph follicles and spleen architecture by histological examination. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | Bomedemstat |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
-
-
CAS:1820934-93-7
$1400.00 / 25mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$117.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2025-07-15 |
United States